Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma
Craig Gibbs, PhD, MBA, appointed President and Chief Executive Officer Ellen Lubman, MBA, joins as Chief Business and Strategy Officer Oncology veteran Tim Clackson, PhD, appointed to the Board of Directors FDA grants Safe to Proceed for the Pivotal Phase 3 sTEADfast Clinical Study SAN...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.